CNW/ - Hoffmann-La Roche Limited (Roche Canada) is proud to announce that Health Canada has granted market authorization for ...

The capital infusion will be used for expansion and to accelerate investment in technology, data reporting and client ...

JSW Energy plans to raise ₹10,000 crore through qualified institutional placement and another ₹3,000 crore from the promoters ...

TNKase is the first stroke medicine approved by the FDA in nearly 30 years. The U.S. Food and Drug Administration (FDA) has approved Genentech’s TNKase (tenecteplase), a thrombolytic or ...

Introduction: The diagnosis of acute central retinal artery occlusion (CRAO) is commonly delayed in emergency departments (ED) where ophthalmologists are rarely available for immediate consultation.

The researchers observed no significant differences between tenecteplase and alteplase in terms of effectiveness or safety outcomes for the overall cohort after adjustment for covariates. HealthDay ...

The 5-second intravenous bolus offers faster, simpler administration than Activase. HealthDay News — The U.S. Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or ...

The US Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults. HealthDay News — The U.S. Food ...

THURSDAY, March 6, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic ...

Roche’s RHHBY member company, Genentech, announced the FDA approval of TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke (AIS) in adults. As a ...